XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma - 26/02/23
Abstract |
Emerging studies have suggested that exportin-1 (XPO1) plays a pivotal role in hepatocellular carcinoma (HCC). However, the underlying mechanism of XPO1 in HCC sorafenib resistance remains enigmatic. The expression of XPO1 in HCC tumor tissues and sorafenib-resistant (SR) cells were analyzed by bioinformatics analysis, immunohistochemistry (IHC) and Western blotting. The interaction mechanism between XPO1 and Nucleophosmin (NPM1) was investigated by immunoprecipitation (IP), Mass-spectrometric (MS) analysis, immunofluorescence colocalization, CRISPR/CAS9 technology and RNA-seq. Analyses were also conducted on KPT-8602 and sorafenib's combined therapeutic effect. Our findings unraveled that the XPO1 overexpression was observed in HCC, and correlated with poorer survival. Knockdown of XPO1 inhibited the migration and proliferation of HCC cells, and also reduced the resistance of HCC cells to sorafenib. Mechanistically, XPO1 interacted with the C-terminus of NPM1 and mediated the acetylation of NPM1 at lysine 54 to maintain sorafenib resistance. XPO1 was bound to Vimentin, resulting in the epithelial-mesenchymal transition (EMT) progression in sorafenib-resistant cells. KPT-8602 in combination with sorafenib suppressed the tumor growth. These results highlighted the therapeutic value of targeting XPO1 in overcoming sorafenib resistance. The combinational treatment of KPT-8602 and sorafenib might be an improved therapeutic option.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
To maintain sorafenib resistance, XPO1 interacted with the C-terminus of NPM1 and facilitated the acetylation of NPM1 at lysine 54 in HCC cells. To increase Vimentin's stability, XPO1 was bound to it, which caused the EMT progress in sorafenib-resistant cells. Sorafenib and KPT-8602 together inhibited tumor growth.
To maintain sorafenib resistance, XPO1 interacted with the C-terminus of NPM1 and facilitated the acetylation of NPM1 at lysine 54 in HCC cells. To increase Vimentin's stability, XPO1 was bound to it, which caused the EMT progress in sorafenib-resistant cells. Sorafenib and KPT-8602 together inhibited tumor growth.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | High expression of XPO1 is associated with poor survival of HCC patients. |
• | Knockdown of XPO1 inhibits the proliferation and sorafenib resistance of HCC cells. |
• | XPO1 mediates the acetylation of NPM1 at Lys54 to maintain sorafenib resistance. |
• | XPO1 binds to Vimentin, resulting EMT progression in sorafenib-resistant HCC cells. |
• | KPT-8602 in combination with sorafenib suppresses the growth of HCC cells. |
Keywords : XPO1, Sorafenib, Acetylation, NPM1, EMT, Hepatocellular carcinoma
Plan
Vol 160
Article 114402- avril 2023 Retour au numéro
Article précédent
- Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system
- Sarina Gadgaard, Johanne A. Windeløv, Sine P. Schiellerup, Jens J. Holst, Bolette Hartmann, Mette M. Rosenkilde
- Tiagabine suppresses pentylenetetrazole-induced seizures in mice and improves behavioral and cognitive parameters by modulating BDNF/TrkB expression and neuroinflammatory markers
- Sana Javaid, Faleh Alqahtani, Waseem Ashraf, Syed Muhammad Muneeb Anjum, Muhammad Fawad Rasool, Tanveer Ahmad, Fawaz Alasmari, Abdullah F. Alasmari, Saleh Abdullah Alqarni, Imran Imran
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?